Variables | Adherent (n=759) | Non-adherent (n=287) | OR (95% CI) | p Value |
---|---|---|---|---|
Treatment types | ||||
PGA monotherapy* (ref.) | 352 (77.4) | 103 (22.6) | 1 | 0.005 |
Non-PGA monotherapy | 56 (63.6) | 32 (36.4) | 1.953 (1.200 to 3.177) | |
Any combination therapy† | 351 (69.8) | 152 (30.2) | 1.480 (1.107 to 1.979) | |
Prescribed daily number of instillation† | 1.82±1.04 2 (1, 2) | 2.22±1.38 2 (1, 3) | 1.321 (1.182 to 1.477) | <0.001 |
Number of eye-drops† | 1.2±0.5 1 (1, 1) | 1.4±0.7 1 (1, 2) | 1.603 (1.287 to 1.995) | <0.001 |
Helper/assistant | ||||
Yes | 136 (75.6) | 44 (24.4) | 1 | 0.329 |
No | 622 (72.0) | 424 (28.0) | 1.203 (0.830 to 1.743) |
Data were presented as n (%).
*Only one drug class in use.
†More than two drug classes in use.
‡Mean±SD, median (first quartile, third quartile), Mann-Whitney U test.
PGA, prostaglandin.